Intangible Assets and Goodwill (Notes)

12 Months Ended

Mar. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS AND GOODWILL

Intangible assets consist of the following (amounts in thousands):



	March 31, 2016
	Gross Amount		Accumulated Amortization			Net Amount
Core and developed technology	$	724,883	$	(255,460	)	$	469,423
Customer-related	278,542		(200,331		)	78,211
Trademarks and trade names	11,700		(7,571		)	4,129
In-process technology	54,308		—			54,308
Distribution rights	5,580		(5,302		)	278
Total	$	1,075,013	$	(468,664	)	$	606,349



	March 31, 2015
	Gross Amount		Accumulated Amortization			Net Amount
Core and developed technology	$	549,415	$	(189,149	)	$	360,266
Customer-related	262,769		(192,283		)	70,486
Trademarks and trade names	13,180		(6,979		)	6,201
In-process technology	67,142		—			67,142
Distribution rights	5,580		(5,258		)	322
Total	$	898,086	$	(393,669	)	$	504,417

The Company amortizes intangible assets over their expected useful lives, which range between 1 and 15 years. During the year ended March 31, 2016, as a result of the acquisition of Micrel, the Company acquired $175.8 million of core and developed technology which has a weighted average amortization period of 10 years, $71.1 million of customer-related intangible assets which have a weighted average amortization period of 5 years, $5.6 million of intangible assets related to backlog with an amortization period of 1 year and $21.0 million of in-process technology which has a weighted average amortization period of 10 years and will begin amortization once the technology reaches technological feasibility. In fiscal 2016, $33.8 million of in-process technology reached technological feasibility and was reclassified as core and developed technology and began being amortized over its estimated useful life.

The following is an expected amortization schedule for the intangible assets for fiscal 2017 through fiscal 2021, absent any future acquisitions or impairment charges (amounts in thousands):



Year ending March 31,	Projected Amortization Expense
2017	$137,321
2018	110,811
2019	94,573
2020	76,683
2021	50,974

Amortization expense attributed to intangible assets was $179.3 million, $181.0 million and $99.4 million for fiscal years 2016, 2015 and 2014, respectively. In fiscal 2016, $3.6 million was charged to cost of sales and $175.7 million was charged to operating expenses. In fiscal 2015, $3.8 million was charged to cost of sales and $177.2 million was charged to operating expenses. In fiscal 2014, $4.7 million was charged to cost of sales and $94.7 million was charged to operating expenses. The Company recognized impairment charges of $0.6 million, $1.9 million and $0.4 million in fiscal years 2016, 2015 and 2014, respectively.

Goodwill activity for fiscal years 2016 and 2015 was as follows (amounts in thousands):



	Semiconductor Products Reporting Unit			Technology Licensing Reporting Unit
Balance at March 31, 2014	$	256,897		$	19,200
Additions due to the acquisition of Supertex	143,160			—
Additions due to acquisition of controlling interest in ISSC	154,399			—
Adjustments due to other acquisitions	624			—
Foreign currency translation adjustments	(3,009		)	—
Balance at March 31, 2015	552,071			19,200
Additions due to the acquisition of Micrel	440,992			—
Adjustments due to the acquisition of ISSC	389			—
Balance at March 31, 2016	$	993,452		$	19,200

At March 31, 2016, the Company applied a qualitative goodwill impairment screen to its two reporting units, concluding it was not more likely than not that goodwill was impaired. Through March 31, 2016, the Company has never recorded an impairment charge against its goodwill balance.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details